HPV – Page 37 – Oral Cancer News

Study Endorses HPV Testing for All Women Over 30

Source: Medscape.com LONDON (Reuters) Dec 15 - New DNA tests looking for the virus responsible for most cases of cervical cancer make sense for all women aged 30 or over, since they can prevent more cases of cancer than Pap smears alone, Dutch researchers say. Results of a five-year study involving 45,000 women provided the strongest evidence yet in favor of using human papillomavirus (HPV) testing, Dr. Chris Meijer and colleagues from the VU University Medical Centre in Amsterdam reported in The Lancet Oncology on December 15. In recent years, tests for high-risk HPV strains have been developed by companies including Roche and Qiagen. The new tests are known to work well in detecting HPV, but the Dutch study is the first to show they are better than Pap smears alone over two screening rounds set five years apart. The researchers, who looked at women aged 29 to 56, said use of HPV tests led to earlier detection of pre-cancerous lesions, allowing for treatment that improved protection against cancer. Dr. Hormuzd Katki and Dr. Nicolas Wentzensen from the U.S. National Cancer Institute said the results reinforced earlier findings, and provided "overwhelming evidence" of the benefits of including HPV testing in cervical screening programs. The government-backed U.S. Preventive Services Task Force currently urges women who have been sexually active and have a cervix to get Pap smears at least every three years. However, the group recommends against routinely screening women over 65 if they had normal results on a recent Pap [...]

Oral Cancer Foundation News Team - A2011-12-27T11:06:49-07:00December, 2011|Oral Cancer News|

Biosciences aims to lower oral cancer mortality with simple screening test

Source: www.proactiveinvestors.com Author: Amanda Brandon Vigilant Biosciences is a privately held medical technology company based in Norcross, Georgia focused on improving healthcare products to improve patient care. Their most recent research efforts center on early oral cancer detection. In the United States, approximately 37,000 people will be diagnosed with oral cancer this year and its most common risk factor is exposure to the human papillomavirus (HPV). Nearly 40 percent of oral cancer patients will die within five years of diagnosis. The high mortality rate for oral cancer is due to late discovery of the malignancy. In its early stages, the disease can either present no symptoms or the symptoms are often mistaken for other conditions. VigilantBIO is currently trialing an easy-to-use, low-cost and noninvasive oral cancer screening product which tests the saliva (a very desirable biofluid). The patient and practitioners (e.g. dentists, hygienists, periodontists) benefit from the simplicity of the test – no venipuncture means higher test participation and no specialized staff is required to perform the test. In the oral clinical setting, this is ideal because it does not interfere with chair turnover ratio. In addition, test results can be delivered at the point of care. When oral cancer is detected early, patients experience an 80-90 percent survival rate. Combined with the lowered treatment cost (an estimated 36 percent) and easy-to-implement product for oral care practitioners, the early detection product appears to be a winner for all involved. With two clinical trials in process at the University of Miami, [...]

Oral Cancer Foundation News Team - A2011-12-22T15:21:40-07:00December, 2011|Oral Cancer News|

Girls-Only Vaccine Could Be Best Weapon Against HPV

Source: Jezebel.com A new study argues that vaccinating boys against HPV isn't the best use of resources, since vaccinating more girls will actually lead to a greater reduction in overall infections. However, there are also political implications to consider. Back in October, I wrote that the rise of HPV-related throat cancer in men was an excellent argument for vaccinating boys against the virus. And later that month, the CDC extended its vaccine recommendation to include boys as well as girls. But now, researchers say that focusing on vaccinating more members of one sex may be more effective than trying to vaccinate both. In a study published in PLoS Medicine, Johannes A. Bogaards used mathematical modeling to determine which vaccination strategy would lead to the greatest reduction in HPV prevalence. They found that increasing the percentage of girls vaccinated would actually have the biggest effect. Bogaards et al write, "We show that, once routine vaccination of one sex is in place, increasing the coverage in that sex is much more effective in bolstering herd immunity than switching to a policy that includes both sexes. Universal vaccination against HPV should therefore only become an option when vaccine uptake among girls cannot be further increased. Adding boys to current vaccination programs seems premature, because female coverage rates still leave ample room for improvement in most countries that have introduced HPV vaccination. So far, only three countries have achieved a three-dose coverage of 70% or more in females." The authors do note that while [...]

Oral Cancer Foundation News Team - A2011-12-22T14:15:49-07:00December, 2011|Oral Cancer News|

Boys need the cervical cancer jab, too

Source: www.telegraph.co.uk Author: Max Pemberton Few politicians will ever admit they are wrong, so I salute health ministers who have finally capitulated to medical opinion and last month announced a U-turn on the cervical cancer vaccine that is given to 12- and 13-year-old girls. Until now, Cervarix, which protects against two strains of the human papilloma virus (HPV) that are a factor in at least 70 per cent of diagnoses, has been the NHS vaccine of choice. However, another vaccine, Gardasil, also protects against a further two strains of HPV which cause genital warts, the most common sexually-transmitted infection, requiring costly and unpleasant treatment. As doctors have been arguing for some time, this has important public health implications. The current cost to the NHS of treating the 100,000 new cases of genital warts in England each year is £23 million. In several countries, including Australia, where Gardasil has been used in nationwide vaccination programmes, a 75 per cent decrease in the number of new cases of genital warts in the past three years has been reported. Critics of NHS policy complained that Cervarix was chosen over Gardasil not on the basis of clinical efficacy but because its manufacturers offered it at a discounted price, making it the most cost-effective. Indeed, many doctors have admitted in the medical press that they have bought Gardasil for their daughters privately, while they had to give their patients Cervarix. But ministers have seen sense as now Gardasil will be available on the NHS. But the [...]

Oral Cancer Foundation News Team - A2011-12-05T09:29:57-07:00December, 2011|Oral Cancer News|

Higher level of education linked to decreased mortality rates for oral cavity, pharynx cancers

Source: www.hemonctoday.com Author: Camille Ragin, PhD, MPH Overall mortality rates for oral cavity and pharynx cancer declined for all patient groups from 1993 to 2007, but high school graduates experienced the largest reductions in mortality compared with those who attained less than 12 years of education. Black men (–4.95%) and women with 12 years of education (–3.72%) experienced the largest decline in mortality. Black women with more than 12 years of education were the only group that did not experience significant decreases in mortality. Mortality rates increased significantly among all white men, except for those with more than 12 years of education. “Mortality rates for patients with oral cavity and pharynx cancers decreased significantly among men and women with more than 12 years of education, regardless of race/ethnicity (except for black women), whereas rates increased among white men with less than 12 years of education,” the researchers wrote. “Throughout the entire study period, mortality rates have remained highest among the least educated and lowest among those with some college education, regardless of sex or race/ethnicity.” Only patients with at least 12 years of education experienced decreases in mortality for HPV-unrelated cancer sites. Mortality rates increased 2.72% per year for white men with less than 12 years of education (P,.01). Conversely, mortality rates for HPV-related cancers decreased among black men. Among white men, mortality rates increased 1.58% per year for HPV-related cancers during the study period. People with more education typically have higher income, more resources and they’re more likely to [...]

Oral Cancer Foundation News Team - A2011-12-05T09:24:59-07:00December, 2011|Oral Cancer News|

The one thing Rick Perry did right: A shot that stops cancer, the politics of sex and HPV prevention

Source: CultureMap.com I don’t like Rick Perry — I never voted for him and worked actively to try to oust him — but in 2006 he tried to do something good for young girls in Texas. He tried to mandate vaccinations for sixth grade girls with a drug that prevented HPV (Human Papilloma Virus), the devil behind cervical cancer. This virus is responsible for the deaths of 4,000 young women each year in the United States. When Perry announced his mandate, the shit hit the fan and his conservative base (which is most of the state) went ballistic. The social conservatives objected to the vaccine as an infringement on parental rights, and small government conservatives were alarmed at Perry’s aggressive use of executive power. Needless to say, Perry backed off, and the vaccine was off to a miserable start. Six years later, fewer than 33 percent of girls ages 11 to 26 have received all three doses of the HPV vaccine, and Perry is still paying a political price for it. Not just for girls Well, it now appears that boys aren’t “immune” from HPV’s effects. After all, girls have to get infected from somewhere, right? Doctors have observed that young men were getting throat cancers that were usually seen in older, tobacco-using men. Also, there was an increase in anal cancers. Who do you think the culprit behind this was? HPV. It turns out that HPV is the most common sexually transmitted disease: between 75 and 80 percent of [...]

Oral Cancer Foundation News Team - A2011-12-02T12:39:52-07:00December, 2011|Oral Cancer News|

Men in doubt still don’t get checked out!

Source: www.easier.com Author: staff Men are almost twice as likely to die from mouth cancer and statistics consistently show they are less likely to consult with a doctor than their female counterparts. But with rates of incidence and mortality rising at an incredible rate, men can no longer afford to ignore the increasing threat of a killer disease. Mouth cancer cases in the UK have almost doubled in the last decade, rising to 6,000 every year with almost 4,000 of those coming from men and although there are some clear early warning signs many postpone seeking professional advice, leaving fatality rates of the disease at 50 per cent. This is supported by data from the Office of National Statistics, which reveals that women are twice as likely to see their GP as men, visiting the doctors an average of six times a year compared to just three for men. Chief Executive of the British Dental Health Foundation, Dr Nigel Carter, puts this failing down to a lack of general cancer health knowledge in men and warns that ignoring the issue can lead to severe problems in future. Dr Carter said: "For almost all types of cancer, men will die more often than women. There's no biological reason that this should be the case so the reason must be purely down to the timing of diagnosis. Unfortunately, when men do go to their GP their condition may be at a far more advanced stage and therefore much more difficult to treat. [...]

Oral Cancer Foundation News Team - A2011-11-27T14:52:41-07:00November, 2011|Oral Cancer News|

Lab at Hershey Medical Center identifies a virus that could kill cancer

Source: www.pennlive.com Author: Nick Malawskey, The Patriot-News This is not the kind of lab we picture when we think of world-changing science. It’s not the clean, spotless modern laboratories of television or movies. It’s a cluttered, workaday environment, where plastic test tubes rub shoulders with petri dishes and tubs of chemicals on busy shelves. The white board isn’t covered with the scrawl of complex mathematical formulas, but reminders of whose turn it is to buy the doughnuts. But it is here, on the fifth floor of the Penn State Milton S. Hershey Medical Center, where Dr. Craig Meyers and his team might have conducted a miracle. What he and his lab claim discovery of is breathtaking in its simplicity. A common virus, omnipresent in the world. When it infects humans, it does no harm. But introduce it into certain kinds of tumors and the virus appears to go wild, liquefying every cancer cell it comes into contact with. It’s the type of discovery that could change the world. And like all great stories of scientific discovery, it begins with a moment of sublime serendipity, not unlike Isaac Newton nodding off beneath an apple tree. A Tiny Virus It’s one of the smallest, simplest viruses and yet adeno-associated virus type 2, or AAV2, could be among the most important agents in modern medicine. That’s because it’s almost perfectly imperfect. For whatever reason, through its evolution, AAV2 developed what would, in most cases, be a dead end — it cannot easily reproduce. [...]

Oral Cancer Foundation News Team - A2011-11-27T14:38:16-07:00November, 2011|Oral Cancer News|

Study Finds- Fewer Dying from Throat & Mouth Cancer in the U.S.

Source: HealthDay News, US News and World Report Author: Staff Death rates improved most for patients with more than 12 years' education Death rates for U.S. patients with throat and mouth cancers decreased between 1993 and 2007, a new study shows. The finding comes from an analysis of National Center for Health Statistics data on white and black men and women, aged 25 to 64, in 26 states. The researchers also found that the largest decreases in death rates for mouth and throat (pharynx) cancers were among black patients with at least 12 years of education. The study appears in the November issue of the Archives of Otolaryngology -- Head & Neck Surgery. Death rates increased among white men with fewer than 12 years of education, according to Dr. Amy Y. Chen, of Emory University School of Medicine and the American Cancer Society, and colleagues. Another study in the same issue of the journal found that poor overall quality of life, pain and continued tobacco use seem to be associated with poorer outcomes and a higher death rate two years after diagnosis for patients with head and neck cancer. The study included 276 patients diagnosed between September 2001 and September 2008. The overall survival rate two years after diagnosis was 90.8 percent. The likelihood of death within two years of diagnosis was: four times higher for those who reported low quality of life than for those who reported a high quality of life; four times higher for those who continued [...]

Charlotte Parker2011-11-22T09:05:47-07:00November, 2011|Oral Cancer News|

Implications of the Oropharyngeal Cancer Epidemic

Source: Journal of Clinical Oncology Chaturvedi et al,1 analyzing specimens back to 1984, validate the long-held hypothesis that infection with human papillomavirus (HPV) has increased oropharyngeal squamous cell carcinoma (OPSCC) incidence in the US. They find the incidence of OPSCC in men—who have higher risks of both HPV-positive and HPV-negative OPSCC than women—similar to that of cervical cancer in women. From 1988 to 2004, incidence of HPV-negative OPSCC decreased in parallel with smoking whereas incidence of HPV-positive OPSCC increased at about 7.5% per year, so the percentage of OPSCC that was HPV-positive went from less than 20% to more than 70%. HPV-positive and HPV-negative OPSCC are etiologically and clinically distinct,2,3 with HPV-positive disease having better outcome.4–6 In the current study,1 the hazard ratio of 0.3 for HPV-positive/HPV-negative in survival analysis essentially balances the difference in prevalence so each form of OPSCC now accounts for a similar number of deaths. Notably, the authors found that outcomes for HPV-positive OPSCC have improved over time, whereas outcomes for HPV-negative OPSCC are as dismal as they were 25 years ago. The authors argue convincingly that vaccination to prevent oral HPV infections should be evaluated and that better treatments for both types of OPSCC should be developed. We are unlikely to get a better picture of the recent history of OPSCC in the United States. This study used all available OPSCC specimens from the three Surveillance, Epidemiology, and End Results (SEER) registries that participate in the Residual Tissue Repositories Program, analyzed them in several ways, [...]

Oral Cancer Foundation News Team - A2011-11-09T15:24:59-07:00November, 2011|Oral Cancer News|